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Abstract
Background. The present work illustrates how magnetic
separation-based blood purification using ultra-strong iron
nanomagnets can be implemented into an extracorporeal
blood purification circuit. By this promising technique, to-
day’s blood purification may be extended to specifically
filter high-molecular compounds without being limited by
filter cut-offs or column surface saturation.
Methods. Blood spiked with digoxin (small molecule drug)
and interleukin-1b (inflammatory protein) was circulated ex
vivo through a device composed of approved blood trans-
fusion lines. Target-specific nanomagnets were continuously
injected and subsequently recovered with the aid of a mag-
netic separator before recirculating the blood.
Results. Magnetic blood purification was successfully car-
ried out under flow conditions: already in single-pass ex-
periments, removal efficiencies reached values of 75 and
40% for digoxin and interleukin-1b, respectively. Circulat-
ing 0.5 L of digoxin-intoxicated blood in a closed loop,
digoxin concentration was decreased from initially toxic
to therapeutic concentrations within 30 min and purifica-
tion extents of 90% were achieved after 1.5 h.
Conclusions. Magnetic separation can be successfully im-
plemented into an extracorporeal blood purification device.
Simultaneous and specific filtering of high-molecular com-
pounds may offer promising new therapeutic tools for the
future treatment of complex diseases, such as sepsis and
autoimmune disorders.
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Introduction
New mechanistic insights into complex diseases (sepsis,
autoimmune disorders) allow for the identification of poten-
tial new therapeutic targets and make high demands on
today’s blood purification techniques [1, 2]. Despite remark-
able achievements of current blood purification systems,
target-specific filtering of multiple compounds remains
a major issue, particularly for molecules differing in phys-
icochemical character (i.e. mass, size, charge) and high-
molecular weight compounds, such as proteins. Where
diffusion is slow (large target molecules) and filtration is
not appropriate (e.g. due to filter cut-offs), patients require
(centrifugal) plasma exchange (loss of plasma, risk of trans-
fusion reactions) or blood purification through adsorbents.
New technologies, such as antibody-coated adsorbents [3]
or microsphere-based detoxification systems (MDS) [4, 5]
are now being introduced to specifically aim at therapeutic
targets. The use of spherical nonporous particles as adsorb-
ents has been shown to benefit from the intrinsically better
surface accessibility (no pore diffusion) due to higher exter-
nal surface areas and shorter diffusion distances compared to
membranes [6]. Most recently, we introduced the concept of
magnetic blood purification using target-specific metal
nanomagnets to selectively and efficiently remove toxins
from whole blood in small volume batches [7]. In this
approach, ligands (e.g. antibodies) immobilized on tiny
free-flowing magnetic particles specifically capture noxious
compounds. By applying external magnetic gradient fields,
the toxin-loaded nanomagnets can be immediately separated
and removed from the blood.
To bring this promising technology one step closer to
clinical application, a first implementation into a continu-
ously operating extracorporeal circuit was developed.
Target-specific (e.g. antibody functionalized) metal nano-
magnets are continuously injected into a continuous blood
flow where they specifically capture the desired compounds.
Subsequent removal of the pathogen-loaded nanomagnets
from the bloodstream by continuous magnetic separation
allows recirculation of the purified blood. In order to
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demonstrate the potential of this new approach to remove
molecules completely differing in character, digoxin and
interleukin-1b (IL-1b) were used as model compounds
[7]. Digoxin (MW 780 g/mol) is a typical representative of
a small molecule drug with a narrow therapeutic window. In
contrast, the much larger interleukin-1b (MW 17 000 g/
mol) is a pro-inflammatory protein. Among other cytokines,
it plays a crucial role in the orchestration of inflammatory
processes, such as infections [8]. Digoxin and IL-1b anti-
bodies were anchored on the carbon surface of highly mag-
netic carbon-coated metal nanomagnets and applied as
capturing moieties. Using these two model compounds,
we demonstrate how magnetic separation can be success-
fully implemented into an extracorporeal blood purification
device allowing for fast and efficient clearance rates. This
raises attractive opportunities for future therapeutic strat-
egies, where we remove a noxious compound from a pa-
tient’s blood rather than attempting a treatment through
addition of another compound (i.e. drug) to counteract the
negative effect of the pathogen.
Materials and methods
Synthesis of target-specific nanomagnets
Carbon-coated iron nanoparticles of core/shell geometry (C/Fe, mean di-
ameter 30 nm, saturation magnetization 150 emu/g, specific surface area 30
m2/g) were manufactured and washed in acid solution (1 week in HCl, 24
vol%) prior to use in order to dissolve incompletely coated particles follow-
ing previously reported procedures [6, 7]. The nanomagnets were employed
to magnetically tag digoxin antibody fragments (Beacon Pharmaceuticals
Ltd, Kent, UK) and human interleukin-1b (IL-1b) antibodies (eBioscience,
Inc. San Diego, CA).
Anti-digoxin-functionalized nanomagnets (C/Fe-anti-digoxin) were
obtained via a stepwise procedure as previously reported [7]: briefly,
anti-digoxin FAB fragments (antigen binding fragments) were covalently
linked to an amine-reactive crosslinker (MAL-dPEG24-NHS ester;
Quanta Biodesign, Powell, OH) on the NHS end. Subsequently, the
FAB-crosslinker complex was covalently bound to thiol-functionalized
nanomagnets.
For the synthesis of anti-interleukin-1b nanomagnets (C/Fe-anti-
IL-1b), interleukin-1b antibody was tagged by the aid of a third-party
compound: streptavidin (Leinco Technologies, Inc. St. Louis, MO) was
first physisorbed on the nanomagnets’ outer shells. Biotinylated anti-
human IL-1b was then anchored onto the streptavidin-covered
nanomagnets.
Magnetically tagged agents were stocked in hydroxyethyl starch (Tetra-
span 6%; B. Braun Medical AG, Sempach, Switzerland, containing hydrox-
yethyl starch 6%) and ultrasonicated for short periods (<3 min) before
usage. Good dispersion stability was achieved up to nanomagnet concen-
trations of 5 mg/mL (see Supplementary Materials). Nanomagnet concen-
trations in the used dispersions were kept as high as possible in order to
minimize the volume added to the blood.
Blood
Blood for experiments was withdrawn from healthy volunteers and stabi-
lized with sodium heparin (25 000 U, 5 mL, B. Braun Medical AG) at 250
U/mL. Blood used in continuous experiments (500 mL) was purchased
from Blutspende Zu¨rich (Schlieren, Switzerland) as separate bags of freshly
frozen plasma (FFP, A1) and erythrocyte concentrate (EC, A1) and then
reconstituted.
Construction of a device for continuous magnetic blood purification
An extracorporeal circuit was assembled of approved transfusion sets
(Dispomed, Gelnhausen, Germany) as follows: a line equipped with a
silicon injection port and a 10-mL chamber (art. 51800) was connected to
extension lines (art. 51130), all lines having inner diameters of 3 mm. To
drive fluid flow, two different peristaltic pumps were used: REGLO
Digital (Ismatec SA, Glattbrugg, Switzerland) for pumping the particle
dispersion and a haemofiltration-approved pump head supplied by In-
fomed SA (Geneva, Switzerland) for the blood flow. During experi-
ments, the nanoparticle dispersion container was shook continuously
while being pumped. Dosing was kept constant over time in order to
grant a constant concentration of nanomagnets in the device.
A multiline injection system was developed in order to inject the nano-
particle dispersion. Tygon standard tubing (R-3607, 0.27 mm; Ismatec
SA) was slipped onto stainless steel cannulas (Ismatec SA, art.ISM
581), which were then used as injection nozzles collocating them into
the injection port by perforation.
For the magnetic separation, the blood purification line was passed
through a magnetic separator (average field intensity ~0.5 T). High-field
gradients within the tubing were achieved by using an assembly of mag-
netized steel wires as initially proposed by Bockenfeld et al. [9] (detailed
description in Supplementary Materials). Nanomagnets were subject to
intense gradient fields which made them gradually deviate from the blood
flow trajectory and eventually stick to tubing walls.
Sample collection
Single-pass pathogen removal efficiencies were determined by collecting
freshly purified blood via a three-way connector (Dispomed Witt oHG, art.
70017) after the magnetic separator (open loop configuration). Samples for
the continuous blood purification experiments were withdrawn from the
mixed blood reservoir, where the contaminant concentration only gradu-
ally lowered over time (closed loop configuration).
Chemical analyses
Digoxin concentration was measured by the clinical chemistry laboratory
in the University Hospital Zurich. The lower limit of detection was
0.2 nmol/L. Interleukin-1b concentrations were measured in duplicate
by commercial enzyme-linked immunosorbent assays (BD Biosciencies,
Allschwil, Switzerland) at a lower limit of detection of 1 pg/mL.
Theoretical estimate for clearance efficiency
The theoretical pathogen removal efficiency was calculated assuming con-
stant per-pass removal efficiency and an ideally mixed blood reservoir (ho-
mogenous toxin concentration in the tank). The corresponding equation
describing the evolution of the toxin concentration in the blood reservoir is
given below. The concentration is denoted as C and C0 is the initial concen-
tration of the noxious compound in the tank:
C ¼ C0  e
VR xt
VT s
and t is the time elapsed from the beginning and s denotes the cycle time.
The ratio t/s equals the number of cycle runs through the purification unit.
VR and VT are the extracorporeal and the total volume, respectively, and x
is a fixed per-pass removal (toxin concentration in the blood leaving the
extracorporeal device relative to the toxin concentration entering the de-
vice). A brief derivation of the clearance equation can be found in the
Supplementary Materials.
Results
Assembly of a magnetic blood purification device
A first prototype device of magnetic separation-based
continuous extracorporeal blood purification was assem-
bled from three parts: (i) an injection port for nanomagnet
administration into the bloodstream, (ii) a contact chamber
where nanomagnets bind to the target molecules and (iii) a
separator unit using magnetic field gradients to remove the
pathogen-loaded nanomagnets from the blood before recir-
culation (Figure 1).
Continuous injection of nanomagnets into the
bloodstream
To overcome limitations of surface saturation that impair
frequent changes of sorbent cartridges in today’s blood
purification, a continuous administration of nanomagnets
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with vacant binding sites is crucial. To address this issue,
an injector having multiple injection ports for continuous
administration of fresh nanomagnets was developed. Multi-
ple nanomagnet dispersions with different target specificity
can be simultaneously connected to the injector and fed
into the blood flow at different rates (Figure 1).
Magnetic nanoparticles with a metallic core were used
to achieve optimal particle separation after treatment. The
use of metal nanomagnets gives access to superior mag-
netic properties (3–10 times higher saturation magnetiza-
tion than traditional iron oxide-based nanoparticles) but
entrains increased agglomeration due to magnetic dipole–
dipole interactions. To prolong dispersion stability, vari-
ous (protein or biopolymer containing) approved products
for intravenous injection were evaluated for the dispersion
of the nanomagnets. Among the polymer-based physio-
logical solutions, hydroxyethyl starch turned out to be
most effective to ensure stable dispersions (5 mg nano-
magnets/mL) while maintaining binding site accessibility
(Figure 1).
Nanomagnet blood contact chamber
After injection of nanomagnets into the extracorporeal
blood circuit, blood contact (area, time) is crucial as it is
immediately linked to the extraction efficiency. In order to
ensure a homogenous concentration of nanomagnets in the
blood and to increase nanomagnet blood contact time (and
thus time for binding), drip chambers of the transfusion sets
with a volume of 10 mL each were employed as contact
chamber(s) (Figure 1). The number of contact chambers
connected allowed for controlling the exact contact time
between particles and blood.
Magnetic separator—continuous separation of
nanomagnets from the bloodstream
Finally, a high-efficiency magnetic separator assembled
according to a concept initially described by Bockenfeld
et al. [9] was used as a continuously operating magnetic
separation unit (Figure 2). The extracorporeal circuit was
passed through the separation unit multiple times (43) in
order to ensure complete particle separation before blood
recirculation (see Figure 2).
Ex vivo blood circulation setting
For continuous blood purification experiments, blood was
filled into a reservoir (tank with a volume of 1 L, Figure 1)
and circulated through the device using an approved
peristaltic pump at 15 mL/min, which has earlier been de-
scribed to be a feasible flow rate in an in vitro haemodial-
ysis model [10]. Particle sedimentation was minimal at this
Fig. 1. Magnetic separation implemented in an extracorporeal blood purification device (A). Nanomagnets dispersed in hydroxyethyl starch (B)
are continuously injected into the bloodstream (C). After capturing the toxins by selective capturing moieties immobilized on the nanomagnet
surface, the toxin-loaded particles are magnetically separated from the bloodstream before the blood is recirculated into the blood reservoir. Ten-
milliliter drip chambers were used to increase the contact time between nanomagnets and blood and to ensure homogenous concentration of
nanomagnets (D).
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flow rate with still reasonably high nanomagnet-blood con-
tact time. Approved transfusion lines were assembled into
an extracorporeal circuit with a total volume of 50 mL
(disposable parts) and volume between nanomagnet
injection point and magnetic separator of 30 mL. With
the overall flow rate of 15 mL/min, the corresponding
blood-nanomagnet contact time in the extracorporeal
circuit was 2 min. Based on the results obtained in batch
experiments (see Supplementary Materials and an earlier
study [7]), 0.5 mg of nanoparticles/mL of blood were
applied for both digoxin and IL-1b removal. To demon-
strate continuous magnetic blood purification, in vitro
blood purification runs were performed using both open-
(Figure 3) and closed-loop circuits (Figure 4).
Single-pass blood purification (ex vivo)
Figure 3 reports results of single passes through the mag-
netic blood purification device (‘open-loop configuration’,
blood passes the device only once). The removal efficiency
was determined in samples withdrawn directly after the
separator unit. Significant purification efficiencies were
achieved under continuous conditions: 66 and 38% for
digoxin and IL-1b, respectively. For digoxin, a blood sam-
ple (60 mL) was collected after a first pass purification and
subjected to a second purification cycle (readdition of fresh
nanomagnets with vacant binding sites). Again, purifica-
tion efficiencies of 70% were achieved using the same
nanoparticle dose (0.5 mg/mL) (Figure 3).
Continuous ex vivo blood purification
In order to simulate a more realistic scenario, blood purifi-
cation was operated under continuous mode where the
purified blood was recirculated into the blood reservoir
after leaving the separation unit (closed-loop configura-
tion). Continuous treatment was conducted on 500 mL of
digoxin-spiked blood (5.7 nmol/L). One additional mixing
chamber was added to the circuit in order to prolong effec-
tive contact time to 2.5 min while maintaining a standard
flow rate of 15 mL/min. With respect to the imposed dilu-
tion constraint (20%), overall 100 mL of dispersion of
FeC-anti-digoxin (5 mg/mL) was allowed to be injected
over a time span of 90 min (steady concentration of
0.38 mg nanoparticles/mL). Samples withdrawn after the
separator after the first 2 min of operation allowed for
evaluation of an initial single-pass removal efficiency of
75%. In the following, samples were taken every 4 min
from the blood reservoir (Figure 4). After 30 min, digoxin
concentration was halved and reduced below toxic levels.
One hour later, the treatment was ended at a final purifica-
tion extent of 89%.
Fig. 2. Magnetic separator. A schematic drawing of the distribution of nanomagnets in the blood flow during recollection in the magnetic separator (A).
A magnetic separator operating under continous conditions (B). The blood purification device is passed multiple times through the separation unit to
achieve complete separation of nanomagnets from blood (C).
Fig. 3. Magnetic blood purification under continuous conditions (A).
Samples collected after the separator (open loop configuration) show
nanomagnet concentration-dependent extraction of digoxin (B) and inter-
leukin-1b (C). Subjecting the purified blood to a second purification cycle
shows again a significant decrease in digoxin level (B).
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Theoretical clearance efficiency
The theoretical purification level was calculated based on
the assumptions of an ideally mixed blood reservoir (ho-
mogenous concentration) and a constant fraction of digoxin
being removed in every pass (constant single-pass removal
efficiency). The calculated removal efficiency as a function
of time is shown in Figure 4 as a red line and compared to
the experimental data.
Discussion
We present a first implementation of magnetic separation-
based blood purification [7] into a continuously operating
extracorporeal blood purification device. The feasibility of
magnetic blood purification using functionalized metal core
nanomagnets is proven in ex vivo experiments demonstrat-
ing remarkably high removal efficiencies which are very
promising regarding future treatment in clinically critical
situations. The prototype device for magnetic blood purifi-
cation consists of a disposable unit (conventional approved
transfusion set) where the blood circulates just as in standard
blood purification systems. Magnetic separation-specific
items, such as the nanomagnet injector and the magnetic
separation unit, were designed as reusable units.
The miniaturized multiline injection port system where
dispersed nanomagnets are injected into the extracorporeal
circuit allows for simultaneous injection of nanomagnets
with different target specificity. This is possible via inde-
pendent regulation of every injection line flow rate. Every
line can be connected to a different stock of functionalized
nanomagnets. Such flexibility offers the possibility to per-
form tailored patient-specific substance removal adjusted to
different clinical settings. Using target-specific nanomag-
nets, we claim target selectivity of these magnetically tagged
ligands so far achieved only via MDS (simultaneous and
selective) [11] or FAB-coated columns (Glycosorb) [12,
13]. Moreover, nano-sized particles show comparable
contact surface per weight with respect to membranes or
adsorptive matrixes. No pore diffusion hinders surface ac-
cessibility in the case of free-flowing particles. Thus, the
whole surface is readily accessible and enables uniquely fast
ligand binding.
The better purification efficiency achieved for digoxin
can be explained by different binding characteristics (bind-
ing constant, binding kinetics and compound concentration
range) and different capacity of FeC-anti-digoxin and FeC-
anti-IL-1b nanomagnets. The removal efficiency could be
further optimized by increasing the number of binding sites
per particle (achievable via optimal synthesis) and the use
of antibodies with an even higher binding constant. Theo-
retical clearance was estimated assuming the reservoir as an
ideally mixed tank (homogenous toxin concentration dis-
tribution) and the circuit tract as a converter (a fixed frac-
tion of the incoming substance is constantly converted).
Although the model is rudimental, the theoretical values
(red line) are in good agreement with the experimentally
determined clearance dynamics.
A further fundamental improvement in the proposed ap-
proach is represented by the continuity in supplying fresh
adsorptive surface carrying vacant binding sites. This over-
comes saturation, an inevitable event for any non-regenerat-
ing sorbent. For example, if nonspecific adsorption takes
place, media capture desired and undesired compounds,
e.g. as observed by De Vriese et al. [14, 15] on the adsorbent
Hopsal AN69: anti-inflammatory compounds (i.e. IL-1
receptor antagonist) were subject to adsorption as much as
pro-inflammatory agents were. This unfavourable fact ac-
celerates the saturation process (loss of target-binding sites
on the adsorbent) and thus decreases adsorption rates be-
sides removing a wider class of compounds than what may
be targeted.
In the continuous ex vivo purification setting used here,
the major assumption, also previously made by Uchino
et al. [16], is that a blood container is able to replicate a
human body. This limited model cannot take into account
that the human body dynamically interacts with changes
caused by extracorporeal factors, i.e. septic patients contin-
uously produce cytokines (i.e. de novo synthesis) while
undergoing therapy [2].
The experimental conditions used in the investigated
ex vivo blood purification experiments can be compared to
real clinical dimensions [17] with potential for scale up. It is
expected that the use of multiple lines in parallel would
allow analogous extraction efficiencies for a patient’s whole
blood volume (4.5 L) using similar conditions as in the
Fig. 4. Continuous purification of 500 mL digoxin-spiked blood using a
closed-loop configuration where the purified blood is recirculated to the
blood reservoir after the separator. A sample withdrawn directly after the
separator at t¼ 2 min (closed triangles) shows the digoxin concentration in
freshly purified blood. All other experimental points (closed circles) refer
to samples taken from the blood reservoir where the purified blood has
mixed with the intoxicated one, as it would happen in a patient. The red
curve represents calculated clearance dynamics assuming an ideally mixed
blood reservoir and constant removal efficiency.
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ex vivo experiments shown here. Although the transfusion
sets used consisted of clinically approved materials, toxicity
of the injected nanomagnets needs to be thoroughly inves-
tigated before the magnetic blood purification technology
can be evaluated in first in vivo animal trials.
For clinical application, biocompatibility and/or com-
plete removal of the nanomagnets from blood before recir-
culation are critical and ultimately determine the clinical
applicability of the proposed approach. Various settings
for high-gradient field magnetic separation units for efficient
capturing of magnetic particles under flow conditions have
been developed and are now being tested [9, 18, 19]. Com-
pared to commonly used polymer/metal oxide beads, metal
nanomagnets benefit from their higher magnetic moments
that facilitate magnetic recovery and separation [20]. Matrix
effects of blood (high iron background) and the high chem-
ical stability render quantification of carbon encapsulated
iron nanomagnets complex. First experiments using
water–glycerol mixtures with blood-like viscosity and the
above-mentioned operating conditions (concentrations of
particles before the separator 500 ppm, flow rate of
15 mL/min) showed that<4.5 ppm iron nanomagnets were
detectable after the separator (as determined by atomic ab-
sorption spectroscopy, see Supplementary Materials), cor-
responding to a removal efficiency at least 99%.
Although first haemocompatibility tests of carbon-coated
nanomagnets have shown promising results (normal hae-
molysis and iron metabolism parameters, unaffected blood
coagulation) [7], biocompatibility—with particular focus on
possible interactions with the vascular compartment—needs
to be thoroughly investigated in order to ensure a safe im-
plementation of this technology (e.g. exclude the danger of
embolization). Compatibility of the nanomagnets with the
human body poses a major limitation of the presented blood
purification device at this stage as a small amount of nano-
magnets remains in the blood after treatment (<1%). In a
next step toward clinical application, in vivo performance
and tolerance of magnetic blood purification needs to be
evaluated in animal models (e.g. rodent model of severe
intoxication and gram-negative sepsis) to prove feasibility
in a living organism and to gain insight into dynamic inter-
actions of the organism with the blood purification device
(e.g. activation of coagulation cascade or the complement
cascade, de novo synthesis of cytokines).
Conclusions
Successful implementation of magnetic blood purification
into a continuously operating extracorporeal device proves
the feasibility of using magnetic separation for blood purifi-
cation. Results were achieved in a first implementation of
such a device already showing a promising capacity for
treating a real patient’s blood volume in clinically relevant
time when scaled up. It combines many favorable features
that had been claimed in the past: high clearance rate in rel-
atively short time frame, customization and potentially high
selectivity toward targets and no fluid or beneficial substance
loss [16, 21–25]. In clinically complex situations, e.g. sepsis
and systemic inflammatory response syndrome [26], the sys-
tem proposed here may offer a new tool to be added to the
actual ones. Numerous clinically most attractive hypotheses,
such as cytokine removal in sepsis and its effect on mortality,
now remain to be proved in first animal trials. Detailed in vivo
tests are necessary to bring magnetic separation-based blood
purification closer to daily clinical use.
Supplementary data
Supplementary Materials are available online at http://
ndt.oxfordjournals.org.
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